Skip to Content
Merck
CN

F0778

Felbamate

NMDA glutamate receptor antagonist

Synonym(s):

2-Phenyl-1,3-propanediol dicarbamate

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C11H14N2O4
CAS Number:
Molecular Weight:
238.24
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
247-001-4
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Felbamate,

InChI key

WKGXYQFOCVYPAC-UHFFFAOYSA-N

InChI

1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)

SMILES string

NC(=O)OCC(COC(N)=O)c1ccccc1

solubility

alcohol: soluble

Quality Level

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Anticonvulsant agent that is an allosteric antagonist at the NR2B subunit of the NMDA glutamate receptor; also has γ-aminobutyric acid (GABAA) receptor agonist properties.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

P Glue et al.
Clinical pharmacokinetics, 33(3), 214-224 (1997-10-07)
This article provides an analysis of the degree of agreement between in vivo interaction studies performed in patients with epilepsy and healthy individuals, and in vitro studies which identified the cytochromes P450 (CYP) inhibited by felbamate and those involved in
Mary L Zupanc et al.
Pediatric neurology, 42(6), 396-403 (2010-05-18)
The antiepileptic drug felbamate has demonstrated efficacy against a variety of seizure types in the pediatric population, particularly seizures associated with Lennox-Gastaut syndrome. Postmarketing experience, however, revealed serious idiosyncratic adverse effects not observed during clinical trials, including aplastic anemia and
I E Leppik
Epilepsia, 36 Suppl 2, S66-S72 (1995-01-01)
After the first year of clinical experience, felbamate (FBM) appears to be a valuable antiepileptic drug (AED) for the treatment of intractable epilepsy. However, many patients experience side effects that may discourage continued usage. These may be decreased by using
Manuela Contin et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 878(3-4), 461-465 (2009-12-17)
We present an implementation of a method we previously reported allowing the newer antiepileptic drugs (AEDs) rufinamide (RFN) and zonisamide (ZNS) to be simultaneously determined with lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine (MHD) and felbamate (FBM) in plasma
Kinga K Borowicz et al.
Polish journal of pharmacology, 56(3), 289-294 (2004-06-25)
Felbamate (2-phenyl-1,3-propanediol dicarbamate), a representative of novel antiepileptic drugs (AESs), proved to have broad-spectrum anticonvulsive activity. Particularly beneficial efficacy was found against partial seizures and Lennox-Gastaut syndrome. Therefore, felbamate started to be indicated not only as an adjunctive antiepileptic drug

Related Content

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service